Probiotics, prebiotics and antibiotics in inflammatory bowel disease
- PMID: 15669637
Probiotics, prebiotics and antibiotics in inflammatory bowel disease
Abstract
Probiotics and prebiotics are the sort of therapy that most patients with inflammatory bowel disease (IBD) wish for. They are without significant side effects, except possibly an increase in gas with prebiotics, and so far, appear to be entirely safe. However, are they effective? More than a dozen studies using probiotics in IBD have now been reported, and there is dear benefit in pouchitis and possibly also in Crohn's, although there are so many clinical types of this condition that a clear indication has yet to emerge. For ulcerative colitis (UC) more studies are needed. The use of prebiotics in IBD is only just starting, although significant effects on both the luminal and mucosa-associated flora have been demonstrated in healthy subjects. Antibiotics offer more certain hope in IBD treatment, although with a much greater risk of unwanted effects. Their efficacy in clinical studies varies, with Crohn's disease and pouchitis reporting more benefit than ulcerative colitis. However, the ideal combination of antibiotics, and rationale for their use has not been determined.
Similar articles
-
Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.Curr Opin Gastroenterol. 2009 Jul;25(4):329-33. doi: 10.1097/MOG.0b013e32832b20bf. Curr Opin Gastroenterol. 2009. PMID: 19444096 Review.
-
Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.Proc Nutr Soc. 2007 Aug;66(3):307-15. doi: 10.1017/S0029665107005563. Proc Nutr Soc. 2007. PMID: 17637082 Review.
-
Clinical usefulness of probiotics in inflammatory bowel diseases.J Physiol Pharmacol. 2006 Nov;57 Suppl 9:23-33. J Physiol Pharmacol. 2006. PMID: 17242485 Review.
-
Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?Mol Nutr Food Res. 2008 Aug;52(8):906-12. doi: 10.1002/mnfr.200700147. Mol Nutr Food Res. 2008. PMID: 18384087 Review.
-
Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease.Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:90-5. doi: 10.1111/j.1365-2036.2006.03067.x. Aliment Pharmacol Ther. 2006. PMID: 16961752 Review.
Cited by
-
Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.World J Gastroenterol. 2015 May 21;21(19):5985-94. doi: 10.3748/wjg.v21.i19.5985. World J Gastroenterol. 2015. PMID: 26019464 Free PMC article. Clinical Trial.
-
Altered gut bacterial and metabolic signatures and their interaction in inflammatory bowel disease.Synth Syst Biotechnol. 2021 Nov 11;6(4):377-383. doi: 10.1016/j.synbio.2021.10.003. eCollection 2021 Dec. Synth Syst Biotechnol. 2021. PMID: 34820530 Free PMC article.
-
Effects of probiotic supplements on growth performance and intestinal microbiota of partridge shank broiler chicks.PeerJ. 2021 Dec 1;9:e12538. doi: 10.7717/peerj.12538. eCollection 2021. PeerJ. 2021. PMID: 34917423 Free PMC article.
-
Advances in therapeutic approaches to ulcerative colitis and Crohn's disease.Curr Gastroenterol Rep. 2005 Dec;7(6):475-84. doi: 10.1007/s11894-005-0079-9. Curr Gastroenterol Rep. 2005. PMID: 16313878 Review.
-
Interactions between the microbiota and the immune system.Science. 2012 Jun 8;336(6086):1268-73. doi: 10.1126/science.1223490. Epub 2012 Jun 6. Science. 2012. PMID: 22674334 Free PMC article. Review.